About

Curaderm-BEC5 represents a remarkable journey from folk veterinary wisdom to scientifically validated dermatological treatment. The story begins in the late 1970s when Australian biochemist Dr. Bill Cham heard intriguing reports from farmers about livestock with skin cancers that would rub themselves against the Devil’s Apple plant (Solanum linnaeanum), leading to the regression of their tumors. This traditional observation sparked what would become decades of rigorous scientific investigation.

Dr. Cham began his formal research in the early 1980s, and in 1987 became the first scientist to report that BEC (the active compound derived from these plants) possessed significant anticancer properties. He successfully isolated the active compounds, which turned out to be solasodine rhamnosyl glycosides, including solasonine and solamargine. These glycoside compounds were collectively named BEC, giving Curaderm-BEC5 its distinctive designation.

The cream was first released on the Australian market in 1990, marking the beginning of its clinical application. In 2002, the treatment gained significant credibility when it was endorsed by ten United Kingdom hospitals, including the prestigious Royal London Hospital, following comprehensive clinical evaluations. Phase III trials confirmed Curaderm-BEC5’s efficacy for treating non-melanoma skin cancers, with studies showing a 78% success rate with 8 weeks of treatment and virtually 100% success rate with 12 weeks of treatment.

The scientific foundation behind Curaderm-BEC5 has continued to expand significantly. By 2020, more than 1,800 independently published articles describing the anticancer properties of BEC compounds had been documented, reflecting an explosion in scientific interest. The product has now helped over 100,000 people worldwide improve their skin conditions, establishing it as what the manufacturer describes as a non-toxic, non-invasive alternative to traditional surgical interventions.

After 27 years of research and clinical trials, Dr. Cham formulated the current version of Curaderm BEC5 as a topical cream designed to effectively target non-melanoma skin abnormalities. The treatment is positioned as being particularly suitable for conditions including basal cell carcinomas, squamous cell carcinomas, and actinic keratoses, offering what proponents describe as selective targeting of cancerous cells while leaving healthy tissue unaffected.

As with any medical treatment, particularly for conditions involving skin cancer or pre-cancerous lesions, it remains essential for patients to work closely with qualified dermatologists or oncologists who can provide proper diagnosis, evaluate all available treatment options, and monitor progress throughout any therapeutic approach.